What Pharmaxo does

Pharmaxo is a UK-based pharmaceutical group operating through three wholly-owned subsidiaries—Bath ASU, Pharmaxo Healthcare, and Pharmaxo Scientific—headquartered in Corsham, Wiltshire. Founded circa 2004 (originally as Qualasept/Bath ASU) and rebranded from QPHL to Pharmaxo in October 2022, the group has specialized for over two decades in aseptic compounding services, manufacturing patient-specific and dose-banded chemotherapy, central intravenous additives (CIVAS), and patient-controlled analgesia products. Since July 2024, Pharmaxo has operated as a wholly-owned subsidiary of Australia's Icon Group, integrating it into a global cancer-care platform alongside Slade Health. The group employs over 400 people in the South West of England and produces more than 2,000 sterile pharmaceutical products daily.

The company's revenue model rests on two pillars. Bath ASU generates revenue through contract aseptic manufacturing of pharmaceutical specials supplied to NHS trusts, other pharmaceutical companies, and private providers, with pricing set via NHS frameworks and direct enterprise quotes. Pharmaxo Healthcare operates a clinical homecare business delivering high-tech treatments (oncology, enzyme replacement, biologics) directly to patients in their homes and community settings, alongside a Mobile Treatment Centre fleet and a Virtual Nurse remote training service. No public revenue or pricing schedule exists beyond disclosed entry-level production operator wages of £24,823 annually. The group holds the Queen's Award for Enterprise (2019), carbon-neutral certification through Carbonfund.org, and most recently the 2026 Moondance Cancer Awards Collaborating with Partners Award with Cardiff and Vale UHB.

Customer acquisition is driven by enterprise field sales targeting NHS trusts, integrated care systems, and pharmaceutical companies; distribution channels include direct NHS hospital partnerships, homecare field service, mobile treatment units deployed on-site, and paediatric home/school delivery for enzyme replacement therapy. R&D at Pharmaxo Scientific focuses on pharmaceutical stability research via Knowledge Transfer Partnerships with the University of Bath. In September 2025, Bath ASU validated and implemented MALDI-TOF equipment reducing microbiological contaminant identification time from days to approximately ten minutes—a quality-control capability enhancement implemented in the first full year under Icon Group ownership.

Name

Pharmaxo

Legal name

Qualasept Pharmaxo Holdings Limited

Website

https://pharmaxo.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

Pharmaxo is a UK-based pharmaceutical group specializing in aseptic compounding (chemotherapy, CIVAS, PCA) and clinical homecare delivery, serving NHS trusts, pharmaceutical companies, and patients since 2004 as a subsidiary of Australia's Icon Group.

Ownership category

akta.pro rank

Product category

Pharmaceutical Compounding and Clinical Homecare Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE)

akta.pro secondary industries

Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC), Injectables & Specialty Medication Support (e.g., insulin, biologics) (HSABALAG), In-Home Infusion Pharmacy Support & Coordination (HSABALAH)

Keywords

• Pharmaceutical manufacturing services
• Aseptic compounding services
• Clinical homecare services
• Chemotherapy compounding
• Pharmaceutical specials manufacturing

Headquarters

HQ city

Corsham

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Manufacturing: Bath ASU provides pharmaceutical specials manufacturing including patient-specific chemotherapy, dose banded batch chemotherapy, central intravenous additive service, and patient-controlled analgesia products. Manufactures thousands of life-changing pharmaceutical products weekly.
2. Clinical Homecare Services: Pharmaxo Healthcare delivers high-tech treatments to patients in their own homes and in community-based settings, working with NHS, pharmaceutical companies, private medical providers, and self-funding patients.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Pharmaxo is a UK pharmaceutical group providing aseptic compounding and clinical homecare services. Through Bath ASU it manufactures sterile pharmaceutical specials including patient-specific chemotherapy, dose-banded chemotherapy, central intravenous additives, and patient-controlled analgesia products. Through Pharmaxo Healthcare it delivers high-tech treatments to patients in their own homes and community settings, and operates Mobile Treatment Centres and virtual nursing support.

Product overview

Pharmaxo Group operates as a leading provider of aseptic compounding services and clinical homecare across the UK, comprising three main operating subsidiaries: Bath ASU (pharmaceutical specials manufacturer producing sterile injectable products including chemotherapy and patient-specific medications), Pharmaxo Healthcare (clinical homecare provider delivering treatments to patients in their homes and community settings), and Pharmaxo Scientific (research and development focused on stability research). The group also offers Mobile Treatment Centres for on-site clinic delivery and Virtual Nurses for remote patient training and support, serving NHS trusts, pharmaceutical companies, and patients across multiple therapy areas including oncology, haematology, immunology, and rare diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Bath ASU Aseptic Manufacturing Services Pharmaceutical specials manufacturing service providing patient-specific chemotherapy, dose-banded batch chemotherapy, central intravenous additive service (CIVAS), and patient-controlled analgesia products, producing thousands of sterile pharmaceutical products weekly for NHS trusts and pharmaceutical companies across the UK.
• Pharmaxo Healthcare Clinical Homecare Services Specialist pharmacy and clinical homecare service delivering high-tech treatments to patients in their own homes and community-based settings, working with NHS trusts, pharmaceutical companies, private medical providers, and self-funding patients across multiple therapy areas.
• Mobile Treatment Centre Custom-designed mobile clinic providing immunotherapy and chemotherapy treatments in convenient community locations, enabling NHS trusts to transition patients to out-of-hospital care with full clinical service including manufacturing, dispensing, clinic management, and nurse provision.
• Virtual Nursing Service Virtual nursing team providing patient training via secure video calling to support self-administration of drugs at home for patients across the UK across multiple therapy areas.
• Paediatric Enzyme Replacement Therapy Service Specialist home and school-based enzyme replacement therapy service for paediatric patients with lysosomal storage disorders including mucopolysaccharidosis type I and II (Hurler and Hunter syndromes) and Gaucher disease, managed by a paediatric lead nurse and delivered by trained paediatric nurses.

Quantifiable outcome

• Bath ASU produces over 2000 sterile pharmaceutical products daily
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Six partnerships are on record, tiered core and minor.

• Cardiff and Vale University Health BoardcoreStrategic or Co-development Partner · 25 June 2026Pharmaxo Healthcare partnered with Cardiff and Vale University Health Board for the Delivering Myeloma Treatment at Home initiative, winning the 2026 Moondance Cancer Awards Collaborating with Partners Award.
• Icon GroupcoreStrategic or Co-development Partner · 9 July 2024Pharmaxo joined Icon Group in a strategic partnership marking the establishment of a global compounding operator and Icon's pharmaceutical entry in the UK. Icon Group operates integrated cancer care centres throughout Australia, South East Asia and the UK and owns Slade Health. Ian Muir remains as CEO reporting into Icon Group's global structure. Chris Watt serves as strategic advisor on European strategy.
• University Hospitals of Leicester NHS TrustcoreStrategic or Co-development Partner · 19 December 2023Partnership with University Hospitals of Leicester NHS Trust to provide immunotherapy and chemotherapy treatments at Glenfield Hospital through Pharmaxo's Mobile Treatment Centre. Pharmaxo provides full clinical service including manufacturing, dispensing, clinic management and nurse provision.
• Frimley Health and Care ICScoreStrategic or Co-development PartnerPartnership with Frimley Health and Care ICS supporting their Community Medical Diagnostic Unit (CMDU) service. GP Triage partner East Berkshire Primary Care also involved in the partnership.
• Nuffield HealthminorStrategic or Co-development PartnerIcon Group's strategic partnership with Nuffield Health to bring more cancer treatment capacity to underserved communities across the UK.
• Birmingham Children's HospitalcoreStrategic or Co-development PartnerNHS referral centre for paediatric enzyme replacement therapy service. First paediatric patient referred in May 2023. Excellent clinical relationship pivotal to service growth.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Slade Health: Icon Group's compounding arm in Australia and New Zealand, delivering over 1.2 million infusions annually. Now a sister company to Pharmaxo post-2024 acquisition, providing the most direct comparison for global compounding economics and capability.
• Sciensus (formerly Healthcare at Home Ltd): UK clinical homecare specialist providing home administration of complex medicines including oncology and rare disease therapies. Direct competitor to Pharmaxo Healthcare in the NHS homecare market.
• Nova Laboratories: UK specialist pharmaceutical manufacturer focused on aseptic compounding, sterile injectables, and bespoke medicines. Comparable in scale, regulatory profile, and NHS-contracted sterile manufacturing focus.
• Healthcare at Home: UK clinical homecare provider offering home-based drug administration, nursing, and patient support services. Direct competitor to Pharmaxo Healthcare's clinical homecare model.
• ITH Pharma: UK-based specialist aseptic compounding pharmacy producing CIVAS, chemotherapy, and patient-specific sterile products for NHS hospitals. Direct overlap with Bath ASU's core compounding offering and NHS customer base.
• Alcura (Alliance Healthcare): UK clinical homecare and pharmacy services provider delivering treatments to patients' homes, overlapping directly with Pharmaxo Healthcare's home infusion and nursing services.

Broad incumbents

• Baxter International: Global healthcare company with large sterile injectable manufacturing and home infusion therapy businesses. Comparable in sterile compounding scale and clinical homecare delivery, but operates as a broad incumbent across multiple product lines.
• Clinigen Group: UK-listed pharmaceutical services company providing unlicensed and specialty medicines, clinical trial supply, and homecare services. Comparable business model combining pharmaceutical supply, compounding access, and homecare delivery.
• B. Braun Medical: Global medical device and pharmaceutical manufacturer with significant sterile compounding, infusion solutions, and clinical nutrition offerings. Overlaps with Bath ASU's aseptic manufacturing but at much greater scale and across broader geographies.

Others

• Qualasept Bath ASU Suppliers / Mawdsleys: UK pharmaceutical distribution and specialist services company serving NHS and pharma manufacturers. Functions as an adjacent supplier/distributor in the same NHS pharmaceutical supply chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/PharmaxoHealth

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmaxo